These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 18230575)

  • 1. [Imatinib and solid tumours].
    Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
    Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New oncological treatment principle with imatinib].
    Kuenen BC; Pinedo HM
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
    Scheinfeld N
    J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Imatinib--a new perspective in the treatment of tumors].
    Klener P; Klamová H
    Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal stromal tumors and the evolution of targeted therapy.
    Sanborn RE; Blanke CD
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.
    Gross DJ; Munter G; Bitan M; Siegal T; Gabizon A; Weitzen R; Merimsky O; Ackerstein A; Salmon A; Sella A; Slavin S;
    Endocr Relat Cancer; 2006 Jun; 13(2):535-40. PubMed ID: 16728580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
    Shiba K; Matsumoto T; Hirota S
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical studies with imatinib in 2004].
    Eckhardt S
    Orv Hetil; 2005 May; 146(18 Suppl 1):941-4. PubMed ID: 15921309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
    Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
    Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Imatinib].
    Urabe A
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1191-6. PubMed ID: 12938280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib: a targeted clinical drug development.
    Capdeville R; Silberman S
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):15-20. PubMed ID: 12783370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib. Novartis.
    Radford IR
    Curr Opin Investig Drugs; 2002 Mar; 3(3):492-9. PubMed ID: 12054102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety profile of imatinib in CML and GIST: long-term considerations.
    Thanopoulou E; Judson I
    Arch Toxicol; 2012 Jan; 86(1):1-12. PubMed ID: 21717109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current clinical management of gastrointestinal stromal tumors.
    Tosoni A; Nicolardi L; Brandes AA
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):595-605. PubMed ID: 15270663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate.
    Waller CF
    Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
    Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
    J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
    Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.
    Fiorentini G; Rossi S; Lanzanova G; Biancalani M; Palomba A; Bernardeschi P; Dentico P; De Giorgi U
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):17-20. PubMed ID: 16767900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.